Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctiondiacylglycerol-dependent serine/threonine kinase activity

SMG1 PRKD2 PRKCH PRKCQ

1.25e-06161054GO:0004697
MousePhenoabnormal iris pigment epithelium

COL18A1 TRPM3 FOXC2

3.57e-066803MP:0005199
DomainProt_kin_PKC_delta

PRKCH PRKCQ

1.69e-0441002IPR014376
DomainBcl2-/adenovirus-E1B

PRUNE2 ATCAY

1.69e-0441002IPR022181
DomainBNIP2

PRUNE2 ATCAY

1.69e-0441002PF12496
DomainDAG/PE-bd

PRKD2 PRKCH PRKCQ

1.85e-04211003IPR020454
PathwayREACTOME_BUTYROPHILIN_BTN_FAMILY_INTERACTIONS

BTN3A2 BTN3A1 BTN3A3

3.73e-0512803M27738
Pubmed

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

BTN3A2 BTN3A1 BTN3A3

2.83e-083107322767497
Pubmed

Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.

FLT1 NFATC2 KDR

2.83e-083107318931684
Pubmed

Primate-specific BTN3A2 protects against SARS-CoV-2 infection by interacting with and reducing ACE2.

BTN3A2 BTN3A1 BTN3A3

1.13e-074107339142074
Pubmed

Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology.

BTN3A2 BTN3A1 BTN3A3

2.82e-075107329339503
Pubmed

Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells.

FLT1 PPARG KDR

2.82e-075107322095559
Pubmed

Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.

RALGAPA1 DUSP28 MYCBP2 RNF213 STAM PPM1G SHKBP1 RIF1 KMT2D TOX4 AHNAK CRYBG3 RPA1 KIF22 XPOT

7.98e-0710491071527880917
Pubmed

The cluster of BTN genes in the extended major histocompatibility complex.

BTN3A2 BTN3A1 BTN3A3

9.82e-077107311170752
Pubmed

HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells.

FLT1 PPARG KDR

1.57e-068107321612582
Pubmed

BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.

RALGAPA1 LSG1 MPDZ STAM PPM1G LLGL1 AHNAK CCT8 CRYBG3 RPA1 PLS3 KIF2C

1.96e-067081071239231216
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

DOCK2 PRUNE2 DIS3L ARHGEF18 RNF213 UBE4A TOX4 ATAD3C TRPM3 CCT8

3.08e-064931071015368895
Pubmed

Luzp4 defines a new mRNA export pathway in cancer cells.

SHKBP1 SRRT ACIN1 RPA1 PLS3

5.02e-0680107525662211
Pubmed

An essential developmental function for murine phosphoglycolate phosphatase in safeguarding cell proliferation.

FLT1 PPARG KDR

6.10e-0612107327731369
Pubmed

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

FLT1 KDR

9.38e-06210728356051
Pubmed

Vascular endothelial growth factor and its receptors in normal human testicular tissue.

FLT1 KDR

9.38e-06210729256359
Pubmed

Expression of vascular endothelial growth factor receptors in the endometrium of septate uterus.

FLT1 KDR

9.38e-062107219200976
Pubmed

Production of VEGF receptor 1 and 2 mRNA and protein during endochondral bone repair is differential and healing phase specific.

FLT1 KDR

9.38e-062107220947709
Pubmed

Multiple developmental roles of Ahnak are suggested by localization to sites of placentation and neural plate fusion in the mouse conceptus.

AHNAK KDR

9.38e-062107214516657
Pubmed

Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice.

FLT1 KDR

9.38e-062107215852018
Pubmed

VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.

FLT1 KDR

9.38e-062107225895461
Pubmed

VEGFR1 and VEGFR2 in Alzheimer's Disease.

FLT1 KDR

9.38e-062107229226875
Pubmed

Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye.

FLT1 KDR

9.38e-062107221731737
Pubmed

Expression of VEGF receptors on endothelial cells in mouse skeletal muscle.

FLT1 KDR

9.38e-062107222984559
Pubmed

Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells.

FLT1 KDR

9.38e-06210728126087
Pubmed

Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors.

FLT1 KDR

9.38e-062107232088190
Pubmed

Expression of vascular endothelial growth factor receptors during male germ cell differentiation in the mouse.

FLT1 KDR

9.38e-062107212773425
Pubmed

VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV.

FLT1 KDR

9.38e-062107223977149
Pubmed

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.

FLT1 KDR

9.38e-062107215611243
Pubmed

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

FLT1 KDR

9.38e-062107221343372
Pubmed

Selected angiogenic cytokines in systemic lupus erythematosus patients.

FLT1 KDR

9.38e-062107219811263
Pubmed

Flt1 and Flk1 mediate regulation of intraocular pressure and their double heterozygosity causes the buphthalmia in mice.

FLT1 KDR

9.38e-062107222426483
Pubmed

VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment.

FLT1 KDR

9.38e-062107218174461
Pubmed

The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice.

FLT1 KDR

9.38e-062107219955220
Pubmed

Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.

CASP8AP2 SRRT

9.38e-062107225530566
Pubmed

Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro.

FLT1 KDR

9.38e-062107211824379
Pubmed

Interaction of FLASH with arsenite resistance protein 2 is involved in cell cycle progression at S phase.

CASP8AP2 SRRT

9.38e-062107219546234
Pubmed

T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2.

DOCK2 IL4R

9.38e-062107217767160
Pubmed

Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades.

FLT1 KDR

9.38e-062107220103598
Pubmed

Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer.

FLT1 KDR

9.38e-062107217599955
Pubmed

Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival.

FLT1 KDR

9.38e-062107216793887
Pubmed

The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis.

FLT1 KDR

9.38e-062107223400753
Pubmed

Endothelial progenitor cells induce transplant arteriosclerosis via VEGFR-1/2 activity.

FLT1 KDR

9.38e-062107225437886
Pubmed

Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

COL18A1 KDR

9.38e-062107212029087
Pubmed

Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

FLT1 KDR

9.38e-06210729295307
Pubmed

Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta.

FLT1 KDR

9.38e-062107214668430
Pubmed

Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia.

FLT1 KDR

9.38e-062107223376830
Pubmed

Expression of vascular endothelial growth factor receptor-1/-2 and nitric oxide in unruptured intracranial aneurysms.

FLT1 KDR

9.38e-062107220635108
Pubmed

Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells.

FLT1 KDR

9.38e-062107221168388
Pubmed

Distinct expression patterns of Flk1 and Flt1 in the coronary vascular system during development and after myocardial infarction.

FLT1 KDR

9.38e-062107229158084
Pubmed

Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors.

FLT1 KDR

9.38e-062107212426207
Pubmed

Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells.

PPARG TFF2

9.38e-062107217118693
Pubmed

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

FLT1 KDR

9.38e-062107228220020
Pubmed

Comparative study of human colonic tumor-derived endothelial cells (HCTEC) and normal colonic microvascular endothelial cells (HCMEC): Hypoxia-induced sVEGFR-1 and sVEGFR-2 levels.

FLT1 KDR

9.38e-062107219287991
Pubmed

Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus.

FLT1 KDR

9.38e-062107218356031
Pubmed

The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis.

FLT1 KDR

9.38e-062107222828632
Pubmed

Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.

FLT1 KDR

9.38e-062107230929546
Pubmed

Proangiogenic Effect of Metformin in Endothelial Cells Is via Upregulation of VEGFR1/2 and Their Signaling under Hyperglycemia-Hypoxia.

FLT1 KDR

9.38e-062107229351188
Pubmed

Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?

FLT1 KDR

9.38e-062107212814952
Pubmed

In vivo regulation of mRNA expression of vascular endothelial growth factor receptors (KDR and flt-1) in the human oviduct.

FLT1 KDR

9.38e-062107214967383
Pubmed

Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.

FLT1 KDR

9.38e-062107219333381
Pubmed

Hypoxia-induced reduction of sVEGFR-2 levels in human colonic microvascular endothelial cells in vitro: Comparative study with HUVEC.

FLT1 KDR

9.38e-062107219082506
Pubmed

VEGFR1 and VEGFR2 immunohistochemical expression in oral squamous cell carcinoma: a morphometric study.

FLT1 KDR

9.38e-062107222203933
Pubmed

Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML).

FLT1 KDR

9.38e-062107222153185
Pubmed

Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions.

FLT1 KDR

9.38e-062107218975312
Pubmed

Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment.

FLT1 KDR

9.38e-062107220484670
Pubmed

Differential role for CD277 as a co-regulator of the immune signal in T and NK cells.

BTN3A2 BTN3A1

9.38e-062107221918970
Pubmed

The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies.

BTN3A2 BTN3A1

9.38e-062107222846996
Pubmed

The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching.

FLT1 KDR

9.38e-062107218504303
Pubmed

Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes.

FLT1 KDR

9.38e-062107220158393
Pubmed

Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma.

FLT1 KDR

9.38e-062107216786116
Pubmed

Protein kinase C η is required for T cell activation and homeostatic proliferation.

PRKCH PRKCQ

9.38e-062107222155788
Pubmed

A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.

FLT1 KDR

9.38e-062107230700502
Pubmed

Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling.

FLT1 KDR

9.38e-062107218433297
Pubmed

The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.

FLT1 KDR

9.38e-062107215111299
Pubmed

Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization.

FLT1 KDR

9.38e-06210729828156
Pubmed

Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2.

FLT1 KDR

9.38e-062107217325350
Pubmed

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

FLT1 KDR

9.38e-062107230401688
Pubmed

Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.

FLT1 KDR

9.38e-062107219265665
Pubmed

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

FLT1 KDR

9.38e-062107214996703
Pubmed

Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.

FLT1 KDR

9.38e-062107217376891
Pubmed

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.

FLT1 KDR

9.38e-062107214760936
Pubmed

DC electric stimulation upregulates angiogenic factors in endothelial cells through activation of VEGF receptors.

FLT1 KDR

9.38e-062107221524919
Pubmed

VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.

FLT1 KDR

9.38e-062107223799140
Pubmed

VEGFR2-mediated vascular dilation as a mechanism of VEGF-induced anemia and bone marrow cell mobilization.

FLT1 KDR

9.38e-062107225310988
Pubmed

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

BTN3A2 BTN3A1

9.38e-062107221113407
Pubmed

Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.

FLT1 KDR

9.38e-062107215592523
Pubmed

Macrophages promote epithelial proliferation following infectious and non-infectious lung injury through a Trefoil factor 2-dependent mechanism.

TFF2 IL4R

9.38e-062107230337651
Pubmed

Toll-like receptor-3 stimulation upregulates sFLT-1 production by trophoblast cells.

FLT1 TLR3

9.38e-062107219631980
Pubmed

mRNA expression of nuclear factor of activated T-cells, cytoplasmic 2 (NFATc2) and peroxisome proliferator-activated receptor gamma (PPARG) transcription factors in colorectal carcinoma.

PPARG NFATC2

9.38e-062107228504924
Pubmed

Identification of functional VEGF receptors on human platelets.

FLT1 KDR

9.38e-062107211852061
Pubmed

Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

FLT1 KDR

9.38e-06210729973224
Pubmed

Distinct roles of vascular endothelial growth factor receptor-1- and receptor-2-mediated signaling in T cell priming and Th17 polarization to lipopolysaccharide-containing allergens in the lung.

FLT1 KDR

9.38e-062107220921519
Pubmed

Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.

FLT1 KDR

9.38e-062107231240525
Pubmed

The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.

FLT1 KDR

9.38e-062107230423986
Pubmed

Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction.

FLT1 KDR

9.38e-062107210865839
Pubmed

Inhibition of Vascular Endothelial Growth Factor Receptors 1 and 2 Attenuates Natural Killer Cell and Innate Immune Responses in an Experimental Model for Obliterative Bronchiolitis.

FLT1 KDR

9.38e-062107234774518
Pubmed

Attenuation of VEGFR-2 expression by sFlt-1 and low oxygen in human placenta.

FLT1 KDR

9.38e-062107224260556
Pubmed

H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.

CASP8AP2 TERF2IP SRRT RIF1 KMT2D TOX4 HOXC11 AHNAK ACIN1 SUZ12 DDX41 RPA1 NOP2 KIF22 KIF2C

1.02e-0512941071530804502
Pubmed

Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.

RNF213 SRRT RIF1 KMT2D TOX4 ACIN1 DDX41 NOP2

1.10e-05341107832971831
Pubmed

MYC multimers shield stalled replication forks from RNA polymerase.

RALGAPA1 LSG1 PPM1G SRRT RIF1 AHNAK CCT8 ACIN1 DDX41 RPA1 NOP2 KIF22 KIF2C

1.13e-059891071336424410
Pubmed

K48- and K63-linked ubiquitin chain interactome reveals branch- and length-specific ubiquitin interactors.

RNF213 STAM SHKBP1 RIF1 KMT2D LLGL1 COPS7B USP4 SUZ12 KIF22

1.80e-056041071038803224
GeneFamilyButyrophilins|V-set domain containing|C2-set domain containing

BTN3A2 BTN3A1 BTN3A3

3.39e-0515783458
GeneFamilyAdenosine receptors|V-set domain containing

FAM187A BTN3A2 BTN3A1 BTN3A3 VCAN KDR

7.36e-05163786590
GeneFamilyRho GTPase activating proteins|BCH domain containing

PRUNE2 ATCAY

3.80e-0477821299
GeneFamilyC2 domain containing protein kinases

PRKCH PRKCQ

8.09e-0410782835
GeneFamilyAnkyrin repeat domain containing|POTE ankyrin domain containing

POTEJ POTEH

1.39e-0313782685
CoexpressionBUSSLINGER_GASTRIC_IMMUNE_CELLS

DOCK2 RALGAPA1 SMG1 PRKD2 MYCBP2 RNF213 ZNF831 CDC42EP3 BTN3A2 BTN3A1 TERF2IP RIF1 KMT2D PHF20L1 NFATC2 AHNAK PRKCH PRKCQ SUZ12 RPA1

1.70e-06149210520M40023
CoexpressionDESCARTES_ORGANOGENESIS_ENDOTHELIAL_CELLS

PRKD2 FLT1 ECE1 COL18A1 TLR3 KDR PRKCH OSMR

1.42e-052721058MM3634
CoexpressionGSE36476_CTRL_VS_TSST_ACT_16H_MEMORY_CD4_TCELL_OLD_UP

DOCK2 RALGAPA1 MYCBP2 ARHGEF18 CRYL1 TLR3 PRKCQ

1.49e-051971057M5295
CoexpressionGSE15139_GMCSF_TREATED_VS_UNTREATED_NEUTROPHILS_DN

RALGAPA1 SMG1 FLT1 PPM1G PRKCH PRKCQ XPOT

1.59e-051991057M7099
CoexpressionGSE33374_CD8_ALPHAALPHA_VS_ALPHABETA_CD161_HIGH_TCELL_UP

PRKD2 MPDZ COL18A1 VCAN ACIN1 SMPD2 IL4R

1.59e-051991057M8538
CoexpressionGSE23568_CTRL_VS_ID3_TRANSDUCED_CD8_TCELL_UP

PRKD2 MYCBP2 TERF2IP TOX4 USP4 SMPD2 ABHD8

1.64e-052001057M8514
CoexpressionHUANG_DASATINIB_SENSITIVITY_UP

TNFRSF21 CDC42EP3 BTN3A2 BTN3A3 OSMR

1.77e-05801055M3015
CoexpressionBOYAULT_LIVER_CANCER_SUBCLASS_G1_DN

MPDZ BTN3A2 BTN3A3 TLR3

1.99e-05401054M1883
CoexpressionDESCARTES_ORGANOGENESIS_DEFINITIVE_ERYTHROID_LINEAGE

GDF3 BTN3A2 BTN3A1 BTN3A3

3.49e-05461054MM3654
CoexpressionPETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN

FLT1 ECE1 TNFRSF21 CDC42EP3 VCAN IL4R

4.94e-051621056M1459
CoexpressionGINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN

PPRC1 ARHGEF11 PPM1G SRRT KMT2D LLGL1 COPS7B ACIN1

6.63e-053381058M17094
CoexpressionAtlasalpha beta T cells, T.4Nve.MLN, 4+ 8- 25- 62Lhi 44lo, Lymph Node, avg-3

PRKD2 ARHGEF18 ZNF831 KMT2D NFATC2 PRKCH PRKCQ ABHD8 IL4R

3.91e-053441019GSM538377_500
CoexpressionAtlaskidney_adult_RenMedVasc_Tie2_top-relative-expression-ranked_1000

RALGAPA1 PRKD2 FLT1 RNF213 PPARG ECE1 CDC42EP3 AHNAK TLR3 KDR PRKCH PRKCQ CRYBG3 OSMR

4.93e-0585010114gudmap_kidney_adult_RenMedVasc_Tie2_1000
CoexpressionAtlasCD positive, CD4 Control, 4+ 8- B220-, Spleen, avg-4

PRKD2 ARHGEF18 ZNF831 KMT2D PHF20L1 PRKCH PRKCQ

6.56e-052101017GSM403995_500
CoexpressionAtlasgamma delta T cells, Tgd.vg2-.Sp, TCRd+ Vg2- CD44-, Spleen, avg-3

PRKD2 ARHGEF18 RNF213 ZNF831 KMT2D HECTD2 PRKCH PRKCQ ABHD8

8.74e-053821019GSM476684_500
CoexpressionAtlasCD positive, CD4 Control, 4+8-B220-, Spleen, avg-2

PRKD2 ARHGEF18 ZNF831 KMT2D PHF20L1 PRKCH PRKCQ

9.83e-052241017GSM403994_500
CoexpressionAtlasgamma delta T cells, Tgd.vg2+.act.Sp, TCRd+ Vg2+ CD44+, Spleen, avg-3

DOCK2 PRKD2 ARHGEF18 ZNF831 NFATC2 AHNAK PRKCH PRKCQ ABHD8

1.13e-043951019GSM476678_500
CoexpressionAtlasgamma delta T cells, Tgd.vg2-.Sp.TCRbko, TCRd+ Vg2- CD44-, Spleen, avg-3

DOCK2 PRKD2 ARHGEF18 ITGAD ZNF831 NFATC2 PRKCH PRKCQ ABHD8

1.36e-044051019GSM605796_500
ToppCellCOVID_non-vent-Lymphocytic-T_cell-CD8+_Memory_T_cell|COVID_non-vent / Disease condition, Lineage, Cell class and subclass

RNF213 ZNF831 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH PRKCQ

1.33e-091971089836061acd7f0d5de89b16f52ec679bdf09eac9db
ToppCellRA-10._Endothelium_II|World / Chamber and Cluster_Paper

FLT1 ECE1 COL18A1 TRPM3 VCAN PRKCH OSMR IL4R

2.06e-08189108875c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCellhealthy_donor-Lymphocytic-T_cell-CD8+_Memory_T_cell|healthy_donor / Disease condition, Lineage, Cell class and subclass

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH PRKCQ

2.73e-081961088af00c31612e4fe068e5fccae05368edba46bbd20
ToppCellPBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

RNF213 ZNF831 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

2.73e-081961088418e8e0a51c5cb60e3b903e7d2d800dc8b9f3d5c
ToppCellPBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RNF213 ZNF831 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

2.73e-081961088581fc8c8d42005aacd7b401a2c9d1fc331fb4af7
ToppCellPBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

RNF213 ZNF831 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

2.73e-0819610886beaf0c2799424c59819b286fbb5c1a83d85e4d1
ToppCellPBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RNF213 ZNF831 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

2.73e-081961088c35f2349dfe35baa845f790b9f31673dceac54c0
ToppCellCOVID_vent-Lymphocytic-T_cell-CD8+_Memory_T_cell|COVID_vent / Disease condition, Lineage, Cell class and subclass

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH PRKCQ

2.84e-081971088d4dfb3b561d0783cdbee4e8d27009ad81df695cb
ToppCellCOVID-19-COVID-19_Severe-Lymphocyte-T/NK-gd_T|COVID-19_Severe / Disease, condition lineage and cell class

RNF213 ZNF831 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

3.19e-082001088f72bc3f6606ae77fe1b0a972e35b3ce0727804d9
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK CPLANE1

2.58e-071771087d3e6c768b88b7906f3c7fdd00ba20842212c14b1
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK CPLANE1

2.58e-071771087f8f101c772c043636bedd6b2ec81409b1d2599bf
ToppCellCOVID-19_Mild-Lymphoid_T/NK-NK_activated|COVID-19_Mild / Disease group, lineage and cell class

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK CPLANE1

2.58e-0717710876978a22fef40c8b455342373abe7593f5ede0fa4
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK CPLANE1

2.58e-071771087936ab2b180a052387124f68d0c7f41c0b164e748
ToppCellPBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK CPLANE1

2.58e-071771087d5aeda113afaa2425874394610344570c9078478
ToppCellEndothelial-B-IPF_02|World / lung cells shred on cell class, cell subclass, sample id

PRUNE2 PRKD2 SGSM1 ZNF831 LLGL1 HECTD2 KDR

3.01e-0718110874fe0215d08f03d4e24749d70fce01b7aa22906fd
ToppCelldroplet-Limb_Muscle-nan-3m-Endothelial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRKD2 FLT1 ECE1 CDC42EP3 KDR PRKCH PLS3

4.03e-071891087d52fc275976a625b014fa36f62ef07dddf1ffa43
ToppCelldroplet-Limb_Muscle-nan-3m-Endothelial-endothelial_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRKD2 FLT1 ECE1 CDC42EP3 KDR PRKCH PLS3

4.03e-071891087199cec36fbbc1288771b9edf22143c34ab990af1
ToppCelldroplet-Limb_Muscle-nan-3m-Endothelial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRKD2 FLT1 ECE1 CDC42EP3 KDR PRKCH PLS3

4.17e-0719010870a211e7dc515926b488f04c6248f6c7e61c2da87
ToppCelldroplet-Fat-Mat-18m-Endothelial|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 MAP3K7CL ECE1 CDC42EP3 RYR2 PLS3 FOXC2

4.64e-07193108754024a373e42e1c0bcc327dc084564b83b63a9d4
ToppCelldroplet-Fat-Mat-18m-Endothelial-endothelial_cell|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 MAP3K7CL ECE1 CDC42EP3 RYR2 PLS3 FOXC2

4.64e-07193108781d908594d2983ba7e7c1ec25afdde4315d9690e
ToppCelldroplet-Fat-Mat-18m-Endothelial-Cd36+|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 MAP3K7CL ECE1 CDC42EP3 RYR2 PLS3 FOXC2

4.80e-07194108774d0eaa76f6d9af14110dfe5b4bf9751b99ff6e3
ToppCell3'-Adult-Appendix-Endothelial-blood_vessel_EC-Mature_venous_EC|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CDC42EP3 COL18A1 NFATC2 KDR PRKCH OSMR PLS3

4.97e-0719510876a0460d949ccda7c9fe76870d3ee6c2f60677d61
ToppCellCOVID-19_Severe-Lymphoid_T/NK-gd_T|COVID-19_Severe / Disease group, lineage and cell class

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

4.97e-0719510879990440bda7fac5d00ef80444fab07459be625e1
ToppCellParenchymal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK-NK_CD11d|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DOCK2 ITGAD ZNF831 BTN3A2 BTN3A1 PRKCH PRKCQ

5.70e-0719910877d69785717073491b5fb81bf24db0175f86cd0b0
ToppCell10x_5'_v1|World / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

RNF213 ZNF831 BTN3A2 NFATC2 AHNAK PRKCH PRKCQ

5.70e-0719910870478eafaa2a4819d1bbfb227e6c00d3578429bed
ToppCellBronchial-NucSeq-Immune_Lymphocytic-T-T_CD8-CD8_CTL|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DOCK2 RNF213 ZNF831 BTN3A2 NFATC2 PRKCH PRKCQ

5.70e-071991087eb188b0b457136b6ee485d3b3052baa30d9c0002
ToppCellLPS_IL1RA-Endothelial-Endothelial|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

PRKD2 FLT1 RNF213 ECE1 AHNAK KDR PRKCH

5.89e-07200108772ea9882a8ed26fa1534aeb6ba0d1897dccc20c5
ToppCellLPS_IL1RA-Endothelial|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

PRKD2 FLT1 RNF213 ECE1 AHNAK KDR PRKCH

5.89e-0720010875c092b2ecc081b5d04476c56333c338cd89ab984
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated|COVID-19_Mild / Disease, condition lineage and cell class

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 AHNAK PRKCH

5.89e-0720010872281debd86e5d92e8fe0397aec9ef670800f7471
ToppCellLPS_IL1RA_TNF-Endothelial-Endothelial-Activated_Gen_Cap|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

PRKD2 FLT1 RNF213 ECE1 TNFRSF21 KDR PRKCH

5.89e-0720010873585484c7e24e941708bee471ca607d8ccee74e6
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

SGSM1 ECE1 COL18A1 KDR PRKCQ FOXC2

3.58e-061691086f077e39e41fffe7672541f5b72b80faaf56c597c
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

SGSM1 ECE1 COL18A1 KDR PRKCQ FOXC2

3.71e-06170108635e3945d8a540a3e2cec1b559316265aaad023d1
ToppCellPND01-Endothelial-Endothelial_lymphatic|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

SGSM1 ECE1 COL18A1 KDR PRKCQ FOXC2

3.71e-0617010860ea625abaa25bab93b70b7000e8f90d5c0f9a0fb
ToppCellPND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

SGSM1 ECE1 COL18A1 KDR PRKCQ FOXC2

3.71e-0617010860b5ddc7d452db0a389927a367914f7d257703f7e
ToppCellCOVID-19-kidney-REN+Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type

PPARG COL18A1 HOXC11 TRPM3 OSMR FOXC2

4.24e-0617410868393f0b43c767839c1630bcb952d62b42efc788d
ToppCelldroplet-Heart-4Chambers-18m-Endothelial-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRKD2 FLT1 PPARG KDR PRKCH CNGB1

4.83e-061781086ba2f0585626988b511046630bc16be5c5fec3fb2
ToppCellE16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1-AT1_prolif|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PRSS8 DIS3L C2orf88 STAM ARHGEF11 TOX4

5.31e-061811086f6629fa71bb94405f523f63a9264cacf6d15c5f4
ToppCellFetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

ECE1 RYR2 NFATC2 VCAN OSMR PLS3

5.48e-061821086ed6ae0fd8653f213fe29906a6a4e0729a62e1b75
ToppCellfacs-Limb_Muscle-Muscle_forelimb_and_hindlimb-18m-Endothelial-endothelial_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 PPARG ECE1 CDC42EP3 KDR PRKCH

6.02e-061851086c3105978d971da7d0fad1a717ee29afee5ed6357
ToppCellfacs-Limb_Muscle-Muscle_forelimb_and_hindlimb-18m-Endothelial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 PPARG ECE1 CDC42EP3 KDR PRKCH

6.02e-0618510864cfef50aeed5b3000ce5e864a41c13740b8267b1
ToppCellControl-T_cells-CD8+_T_cells|Control / group, cell type (main and fine annotations)

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

6.02e-06185108602ab64c0166c0646d1d4c6ed110ef0b75a1096d0
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

6.02e-06185108645890fa81c65a48f4fdec164a4c8d0e2831243c0
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

6.02e-061851086585bcfdff85bf43f5aa4cd1b39f7dcf1c78d7b02
ToppCellfacs-Limb_Muscle-Muscle_forelimb_and_hindlimb-18m-Endothelial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 PPARG ECE1 CDC42EP3 KDR PRKCH

6.02e-06185108609256c6f42f59b7eb89160b2ea706172a5b743be
ToppCellCOPD-Multiplet-Multiplet|World / Disease state, Lineage and Cell class

AXIN1 LRRIQ1 NFATC2 PRKCH PRKCQ OSMR

6.60e-061881086186fe1ea328c942910190a4240262c0d8642ea3b
ToppCelldroplet-Limb_Muscle-nan-21m-Endothelial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 ECE1 CDC42EP3 KDR PRKCH PLS3

7.01e-0619010861ff2295c9fc94ea21fff286706b739d0deb032d0
ToppCelldroplet-Limb_Muscle-nan-21m-Endothelial-endothelial_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 ECE1 CDC42EP3 KDR PRKCH PLS3

7.01e-06190108661f2f9fb4b8f47a2a669f6b052214d2ce0c194cd
ToppCelldroplet-Limb_Muscle-nan-21m-Endothelial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FLT1 ECE1 CDC42EP3 KDR PRKCH PLS3

7.01e-061901086d415c8f3d69a8142e95307aeabc6d0e812cd5165
ToppCellCOVID-19-kidney-NK|kidney / Disease (COVID-19 only), tissue and cell type

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

7.01e-061901086e3ca3c9fb9e27670a5dd128dd6564ff98a57159e
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

7.01e-061901086b772a5d281fe016f259ddda80d6f33d949dcac2b
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK-T_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

7.23e-0619110861a2d5fec2bea96da2154b0aed252f1bb35102f6e
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_T/NK-T_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

7.23e-061911086326b4541069efedc8ab409f85bb11f77346dda90
ToppCellEC-Arteriolar_ECs|World / Lineage and Cell class

PRUNE2 FLT1 ECE1 COL18A1 KDR PLS3

7.90e-06194108638f0c52de252101d4bc8633af80002061635e487
ToppCell10x5'-bone_marrow-Lymphocytic_T_CD8|bone_marrow / Manually curated celltypes from each tissue

RNF213 TERF2IP SRRT NFATC2 PRKCH PRKCQ

8.38e-0619610865c9ed3c6e3cbd43b52f0291b5c26dd7f9fadf3da
ToppCell10x5'-bone_marrow-Lymphocytic_T_CD8-Tem/emra_CD8|bone_marrow / Manually curated celltypes from each tissue

RNF213 BTN3A2 SRRT NFATC2 PRKCH PRKCQ

8.38e-061961086f23c33ad10f933250be98e8389a9aa278e876f96
ToppCellCOVID_non-vent-Lymphocytic|COVID_non-vent / Disease condition, Lineage, Cell class and subclass

SMG1 BTN3A2 BTN3A1 NFATC2 PRKCH PRKCQ

8.62e-061971086c672915f8c8c1e948d251f6eaf9f84a5600c1193
ToppCellPBMC-Severe-Lymphocyte-T/NK-CD8+_T-CD8+_Tem|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

RNF213 BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH

8.62e-0619710862b3a56bb1d40bc1284a5931c4e7b373660de5402
ToppCellCOVID-19_Severe-Lymphoid_T/NK-CD8+_Tem|COVID-19_Severe / Disease group, lineage and cell class

RNF213 BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH

8.62e-061971086f0bac4d5c3160933ac3786cec8dadffb35d711ea
ToppCellPBMC-Severe-Lymphocyte-T/NK-CD8+_T-CD8+_Tem-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

RNF213 BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH

8.62e-061971086f73ece3aca28c0db5db0f12e026d42c6c36b9efb
ToppCellPBMC-Severe-Lymphocyte-T/NK-CD8+_T-CD8+_Tem|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RNF213 BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH

8.62e-061971086e70e7d97823a762def3970d94a0e897981a6c922
ToppCellPBMC-Severe-Lymphocyte-T/NK-CD8+_T-CD8+_Tem-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RNF213 BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH

8.62e-061971086bce0135a96910d2bace62a3408a1a6fdac0cf0df
ToppCellT_cells-CTLs|World / Immune cells in Kidney/Urine in Lupus Nephritis

BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH PRKCQ

8.62e-0619710862de34e20915a247bee75aa40495e23c20bb23e18
ToppCellTracheal-NucSeq-Immune_Lymphocytic-T-T_CD8-CD8_GZMK+|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

9.13e-06199108609e0b45529fa9d5fc86da1747b3fb3a238a09aa6
ToppCellCOVID_non-vent-Lymphocytic-ILC|COVID_non-vent / Disease condition, Lineage, Cell class and subclass

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 PRKCH

9.13e-061991086df4f7d5be099e3e6054f3b812ccf70251664e4c0
ToppCellCOVID_non-vent-Lymphocytic-ILC-NK_cell|COVID_non-vent / Disease condition, Lineage, Cell class and subclass

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 PRKCH

9.13e-061991086ed35d747f11f6ea6a5cb7061057f0a98d9e0db99
ToppCellhealthy_donor-Lymphocytic|healthy_donor / Disease condition, Lineage, Cell class and subclass

RNF213 BTN3A2 BTN3A1 BTN3A3 NFATC2 PRKCH

9.13e-0619910862841e16d54acd344ba454f024e285c28abc37319
ToppCell10x_3'_v3-spleen_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_memory_T_cell|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

ZNF831 BTN3A2 TERF2IP SRRT PRKCH PRKCQ

9.13e-06199108669793ef363618030e4546877b3095c587617909f
ToppCellBronchus_Control_(B.)-Immune-TX-T_cells|Bronchus_Control_(B.) / Sample group, Lineage and Cell type

RNF213 ZNF831 BTN3A2 BTN3A1 PRKCH PRKCQ

9.13e-061991086cb4cd42e608126227cbbf2342486550bcd4d0fc9
ToppCellLPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

FLT1 MPDZ RNF213 ECE1 KDR PRKCH

9.40e-062001086dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCellCOVID-19-COVID-19_Severe-Lymphocyte-T/NK-CD8+_Tem|COVID-19_Severe / Disease, condition lineage and cell class

RNF213 BTN3A2 BTN3A1 NFATC2 AHNAK PRKCH

9.40e-06200108631859b8db7ea17e48b7b54e92f0d76aeb755e7ca
ToppCellLPS_only-Endothelial-Endothelial-Activated_Gen_Cap|LPS_only / Treatment groups by lineage, cell group, cell type

PRKD2 FLT1 RNF213 ECE1 KDR PRKCH

9.40e-0620010866f531a418ff25b59a543800cf4bce7b72404ce08
ToppCellControl-Control-Lymphocyte-T/NK-CD8+_Tem|Control / Disease, condition lineage and cell class

RNF213 BTN3A2 BTN3A1 NFATC2 PRKCH PRKCQ

9.40e-062001086fddb3df5b90eb97ef8ed80fac320c1a90903f012
ToppCellBronchial-NucSeq-Immune_Lymphocytic-T-T_CD8-CD8|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DOCK2 ZNF831 NFATC2 PRKCH PRKCQ TRAV26-2

9.40e-06200108620ffb3436d08042f77800513e6ddb3bbc38ae6fe
ToppCellBronchial-NucSeq-Immune_Lymphocytic-T-T_CD8-CD8_GZMK+|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DOCK2 ZNF831 BTN3A1 NFATC2 PRKCH PRKCQ

9.40e-062001086510d84bf7a4621b079e5a7330d25e04508c84a49
ToppCellControl-Plasmablast|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

C2orf88 COL18A1 TXLNB ATAD3C AHNAK

2.77e-051451085fe68582f5a15b9714cb84fa32ac880e13cb69895
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

CASP8AP2 FLT1 KDR PRKCH POTEJ

3.93e-051561085f894fac4e44a23718b20ad80c9677bf4f2118002
ToppCellCOVID-19_Moderate-multiplets|World / disease group, cell group and cell class

RNF213 BTN3A1 NFATC2 TLR3 PRKCH

3.93e-051561085afdc025fa75e7926b1cc182c4a33654a2186abb1
ToppCellfrontal_cortex-Non-neuronal-endothelial_cell|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

FLT1 AHNAK KDR PRKCH OSMR

4.98e-0516410856a41a159134e605b80d5e731f9ed5bc803bb531b
ToppCellfrontal_cortex-Non-neuronal-endothelial_cell-Endo|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

FLT1 AHNAK KDR PRKCH OSMR

4.98e-051641085ec68954fc09b6850273b5e59caa6b09d02151097
ToppCellE16.5-Endothelial-Endothelial_lymphatic|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ECE1 ZNF831 TLR3 KDR FOXC2

5.43e-051671085b93103a868fba63a8910bffb690a6242b9252833
ToppCellE16.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ECE1 ZNF831 TLR3 KDR FOXC2

5.43e-051671085fcd583b1efd0ac883379982ea8e6c54f2c0be268
ToppCellE16.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ECE1 ZNF831 TLR3 KDR FOXC2

5.43e-051671085f6bc63138b7239211fa5f27a8dc799b6e022c0f8
ToppCellE16.5-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ECE1 ZNF831 TLR3 KDR FOXC2

5.43e-05167108526cd8ee5e826e71eaf58d10a906543a6932fb3f9
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

SRRT RIF1 COMMD7 PRKCQ

5.73e-0586108479c4326df78f0a5b3ef13b2fb4e5074934536e35
ToppCelldroplet-Lung-nan-3m-Lymphocytic-T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PHKG1 PRKCQ DSCC1 KIF22 KIF2C

5.75e-051691085df2c9c706bfc9db2bc5726602a49f5f5a94e9481
ToppCelldroplet-Lung-nan-3m-Lymphocytic-Proliferating_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PHKG1 PRKCQ DSCC1 KIF22 KIF2C

5.75e-051691085f6a6d2f614d60395ad9b867ff1cf59eba72b04ce
ToppCellLPS-IL1RA-Lymphocytic_NKT-T_cells-T-cells|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DOCK2 ARHGEF18 ZNF831 NFATC2 PRKCQ

6.08e-051711085539ea88acc6f948efdeae8b69e5c5ffaee29f1d9
ToppCellfacs-Marrow-B-cells-18m-Lymphocytic-BM_CD4_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ATCAY C2orf88 ITGAD PRKCH MAP3K15

6.08e-0517110856f49537f8d3cf18e65aa999fec32ed347ce2da3e
ToppCellfacs-Marrow-B-cells-18m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ATCAY C2orf88 ITGAD PRKCH MAP3K15

6.08e-051711085ab97ae2b127a585f170f028f1c475cdd1b0cdea5
ToppCell5'-Adult-Appendix-Hematopoietic-T_cells-NK_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

DIS3L RNF213 BTN3A2 NFATC2 PRKCH

6.25e-051721085f3c16a62eba1ed190318beee131c71c5150b266a
ToppCellLPS-IL1RA-Lymphocytic_NKT-T_cells|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DOCK2 ARHGEF18 ZNF831 NFATC2 PRKCQ

6.25e-0517210850fc692be845d4225ff8b63bf9195724fc8510c2c
ToppCellLV-17._Lymphocyte|World / Chamber and Cluster_Paper

DOCK2 ZNF831 BTN3A1 PRKCH PRKCQ

6.42e-051731085212f013ff761cbab24a537071739867c08c402a4
ToppCelldroplet-Heart-4Chambers-18m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PRKD2 FLT1 ECE1 KDR PRKCH

6.42e-0517310859a04271c51fae34f547db3206f9ff5857686e45c
ToppCellChildren_(3_yrs)-Immune-natural_killer_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

ITGAD ZNF831 NFATC2 PRKCH PRKCQ

6.60e-05174108533d6b81f31bfcb9c4b30206d88e20b9a94fba4a2
ToppCellE18.5-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC-VEC_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT1 ECE1 TXLNB KDR FOXC2

6.78e-0517510852e54961846c65b185d9bd6e305dd81205579d890
ToppCellE18.5-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FLT1 ECE1 TXLNB KDR FOXC2

6.78e-051751085efa6a05f7417d46141b6e635f258c126b7a03aa1
ToppCellLPS-IL1RA+antiTNF-Lymphocytic_NKT-T_cells-T-cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DOCK2 ARHGEF18 ZNF831 NFATC2 PRKCQ

6.96e-0517610859d4a4dfeebb5a8a0f3ab18c37c8ddc2cd2158575
ToppCellLPS-IL1RA+antiTNF-Lymphocytic_NKT-T_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DOCK2 ARHGEF18 ZNF831 NFATC2 PRKCQ

6.96e-051761085bb41e9478373726eb460af764de0277b2d09928e
ToppCellLPS-antiTNF-Lymphocytic_NKT-T_cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DOCK2 ARHGEF18 ZNF831 NFATC2 PRKCQ

6.96e-051761085ea27e18407b8a13e8212830da859efeb8f158690
ToppCellLPS-antiTNF-Lymphocytic_NKT-T_cells-T-cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DOCK2 ARHGEF18 ZNF831 NFATC2 PRKCQ

6.96e-051761085bfbab3c5b738b3b0b1540f2059d0245fbd8c0031
DrugBupropion hydrochloride [31677-93-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A

PDE4A ECE1 ARHGEF11 RYR2 BTN3A3 PRKCQ OSMR CNGB1

3.58e-0619810483180_UP
DrugOleandomycin phosphate [7060-74-4]; Up 200; 5uM; PC3; HT_HG-U133A

RALGAPA1 PRUNE2 FLT1 SRRT VCAN SMPD2 CNGB1 PCYT1B

3.58e-0619810484615_UP
Drugdarglitazone

FLT1 PPRC1 PPARG VCAN

4.07e-06241044CID000060870
Druglidocaine

PRKD2 STAM RYR2 PHKG1 PRKCH PRKCQ GABRA5

8.90e-061601047CID000003676
DrugAC1NTCGD

PPRC1 PPARG

2.07e-0521042CID005378157
Drug3-(5-methyl-2-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid

FLT1 KDR

2.07e-0521042ctd:C477639
DrugH-Trp-Glu-OH

PPRC1 PPARG

2.07e-0521042CID003634442
Drugrivoglitazone

PPRC1 PPARG

2.07e-0521042CID003055168
Drugnorathyriol

PRKD2 PPARG PRKCH PRKCQ

2.42e-05371044CID005281656
DrugLevonordefrin [829-74-3]; Up 200; 21.8uM; PC3; HT_HG-U133A

MED18 ATP10B LLGL1 VCAN PRKCQ OSMR CNGB1

2.45e-0518710475854_UP
DrugDenatonium benzoate [3734-33-6]; Up 200; 9uM; MCF7; HT_HG-U133A

DOCK2 ECE1 CDC42EP3 SMPD2 PRKCQ OSMR IL4R

3.41e-0519710475480_UP
DrugBenzamil hydrochloride [2898-76-2]; Down 200; 11.2uM; PC3; HT_HG-U133A

PPRC1 ECE1 ARHGEF11 RYR2 SRRT SMPD2 ABHD8

3.64e-0519910474294_DN
Drugphosphorylcholine

PRKD2 PPRC1 RIF1 PRKCH SMPD2 DDX41 PCYT1B

3.88e-052011047CID000001014
Drug1 Em

PRKD2 PPM1G PRKCH PRKCQ PCYT1B

3.95e-05831045CID000446621
DrugPEP005

PRKD2 TLR3 PRKCH DDX41

4.02e-05421044CID006918670
DrugRK-1409B

PRKD2 PRKCH PRKCQ

4.05e-05151043CID003036125
Drugdansyl-DAG

PRKD2 PRKCH PRKCQ

4.05e-05151043CID000129493
DrugAC1LDMDX

PRKD2 PPARG PRKCH PRKCQ

4.42e-05431044CID000621355
Drug1,3-diolein

PRKD2 PRKCH SMPD2 PRKCQ PCYT1B

5.83e-05901045CID000033120
Druglosartan

PRKD2 PPRC1 ATCAY ITGAD COL18A1 VCAN PRKCH PRKCQ PLS3

5.98e-053781049CID000003961
DrugAC1L1JQC

PRKD2 PRKCH PRKCQ

6.01e-05171043CID000005157
Drugdaphnoretin

PRKD2 PRKCH PRKCQ

6.01e-05171043CID005281406
Drugtocopherol

PRKD2 PPRC1 PPARG PRKCH PRKCQ

6.15e-05911045CID000014986
Drugmeranzin

PPRC1 PPARG

6.18e-0531042CID001803555
Drugdrosophilin a

PPRC1 PPARG

6.18e-0531042CID000068088
Drugdihydrosterculic acid

PRKD2 PRKCH PRKCQ

7.19e-05181043CID000160788
Drugprocaine

PRKD2 PPRC1 RYR2 PRKCH PRKCQ GABRA5

7.37e-051531046CID000004914
Drugthiamylal

PRKD2 PRKCH PRKCQ GABRA5

7.43e-05491044CID003032285
DrugTAPP-Br

PRKD2 PRKCH PRKCQ

8.51e-05191043CID000160326
DrugP-38

PRKD2 FLT1 PPRC1 PPARG TLR3 PRKCH SMPD2 DSCC1 DDX41 NOP2 PLS3

1.14e-0461310411CID000200878
DrugKS-619-1

PRKD2 PRKCH PRKCQ

1.16e-04211043CID000128369
DrugK-259-2

PRKD2 PRKCH PRKCQ

1.16e-04211043CID006438946
Drugbroussochalcone A

PRKD2 PRKCH PRKCQ

1.16e-04211043CID006438825
DrugAC1L1B3H

PPRC1 PPARG

1.23e-0441042CID000001267
DrugT67416

FLT1 KDR

1.23e-0441042CID000956683
DrugAC1MHGE4

PPRC1 PPARG

1.23e-0441042CID003025998
Drug3-bromoaniline

FLT1 KDR

1.23e-0441042CID000011562
Drug20-HETE

PRKD2 PPARG VCAN PRKCH PRKCQ

1.27e-041061045CID005283157
Drugphosphine oxide

PRKD2 PRSS8 RYR2 PRKCH PRKCQ

1.33e-041071045CID000166931
DiseaseAdenocarcinoma of large intestine

AXIN1 PHKG1 PRKCH PRKCQ MAP3K15

1.75e-0596985C1319315
DiseaseHemangiosarcoma

FLT1 COL18A1 KDR

2.80e-0518983C0018923
Diseaseprostate adenocarcinoma (biomarker_via_orthology)

KDR PRKCQ

3.27e-053982DOID:2526 (biomarker_via_orthology)
Diseasecerebral cavernous malformation (is_marker_for)

FLT1 KDR

3.27e-053982DOID:0060669 (is_marker_for)
Diseaseallergic contact dermatitis (is_marker_for)

FLT1 KDR

3.27e-053982DOID:3042 (is_marker_for)
Diseasearteriovenous malformations of the brain (is_marker_for)

FLT1 KDR

3.27e-053982DOID:0060688 (is_marker_for)
Diseasetumor necrosis factor-alpha measurement

MED18 ATP10B PHF20L1

5.86e-0449983EFO_0004684
DiseaseRetinal Detachment

COL18A1 PRKCQ

5.89e-0411982C0035305
Diseaseresponse to ondansetron, QT interval

MPDZ TLR3

5.89e-0411982EFO_0004682, EFO_0020997
Diseaseintracranial aneurysm (is_implicated_in)

KMT2D VCAN

7.05e-0412982DOID:10941 (is_implicated_in)
Diseasethyroid gland carcinoma (is_marker_for)

FLT1 KDR

7.05e-0412982DOID:3963 (is_marker_for)
Diseaseretinopathy of prematurity (biomarker_via_orthology)

FLT1 KDR

7.05e-0412982DOID:13025 (biomarker_via_orthology)
Diseasemacular retinal edema (is_marker_for)

FLT1 KDR

7.05e-0412982DOID:4449 (is_marker_for)
DiseaseCalcium channel blocker use measurement

ARHGEF18 RNF213 ZNF831 BTN3A2 NFATC2

7.37e-04213985EFO_0009930
Diseasecolon carcinoma (is_marker_for)

KMT2D TLR3

8.32e-0413982DOID:1520 (is_marker_for)
Diseasepolycystic kidney disease (implicated_via_orthology)

STAM PPARG

9.68e-0414982DOID:0080322 (implicated_via_orthology)
DiseaseKuhnt-Junius degeneration (is_marker_for)

FLT1 TLR3

9.68e-0414982DOID:10873 (is_marker_for)
DiseaseT-Cell Lymphoma

PPARG KMT2D

1.27e-0316982C0079772
DiseaseSchwartz-Jampel Syndrome, Type 1

FLT1 KDR

1.27e-0316982C4551479
DiseaseSeasonal Affective Disorder

PDE4A GPR50

1.27e-0316982C0085159
Diseasepreeclampsia, parental genotype effect measurement

FLT1 ZNF831

1.27e-0316982EFO_0000668, EFO_0005939
DiseaseSpondyloepiphyseal Dysplasia

FLT1 KDR

1.27e-0316982C0038015
DiseaseSchwartz-Jampel Syndrome

FLT1 KDR

1.27e-0316982C0036391
DiseaseMelnick-Needles Syndrome

FLT1 KDR

1.27e-0316982C0025237
DiseaseSpondyloepiphyseal Dysplasia Tarda, X-Linked

FLT1 KDR

1.27e-0316982C3541456
Diseasecarcinoma (implicated_via_orthology)

FLT1 LLGL1 KDR

1.28e-0364983DOID:305 (implicated_via_orthology)
Diseasebreast carcinoma (is_marker_for)

PRSS8 KMT2D KDR

1.40e-0366983DOID:3459 (is_marker_for)
DiseaseVan Buchem disease

FLT1 KDR

1.44e-0317982C0432272
DiseaseKuhnt-Junius degeneration (is_implicated_in)

FLT1 KDR

1.44e-0317982DOID:10873 (is_implicated_in)
DiseaseUremia

FLT1 KDR

1.44e-0317982C0041948
DiseaseConventional (Clear Cell) Renal Cell Carcinoma

FLT1 AHNAK KDR IL4R

1.52e-03148984C0279702
DiseaseDyschondroplasias

FLT1 KDR

1.80e-0319982C0013366
DiseaseOsteochondrodysplasias

FLT1 KDR

1.80e-0319982C0029422
Diseaseexercise test

RYR2 COL18A1

2.00e-0320982EFO_0004328
DiseaseMultiple Epiphyseal Dysplasia

FLT1 KDR

2.00e-0320982C0026760
Diseasecancer (implicated_via_orthology)

FLT1 AXIN1 LLGL1 KDR NOP2

2.03e-03268985DOID:162 (implicated_via_orthology)
Diseasepreeclampsia

FLT1 MYCBP2 ZNF831

2.26e-0378983EFO_0000668
DiseaseAcute Lung Injury

PPARG TFF2

2.42e-0322982C0242488
DiseaseGiant Cell Glioblastoma

PPARG SRRT SUZ12

2.79e-0384983C0334588
DiseaseAutism Spectrum Disorders

GPR50 RYR2 GABRA5

2.88e-0385983C1510586
Diseasepre-eclampsia (is_implicated_in)

FLT1 PPARG

3.12e-0325982DOID:10591 (is_implicated_in)

Protein segments in the cluster

PeptideGeneStartEntry
QLHSEEEIEPMEGPA

ACIN1

431

Q9UKV3
VQPQEHPILSEFCME

ERI2

81

A8K979
GLEPPVLECMEKDHV

ARHGEF18

181

Q6ZSZ5
PNPECDREKMSVRDH

LINC01590

31

Q5TEZ4
EDADLPCHLFPTMSA

BTN3A3

46

O00478
PCSEETDPVHDLMAE

VCAN

1356

P13611
MEQQLAERECPPHAE

COPS7B

231

Q9H9Q2
AHETAPAPLEMEKAC

CRYBG3

1811

Q68DQ2
EDADLPCHLFPTMSA

BTN3A1

46

O00481
EQEDMGLCSLEHLPP

ARHGEF11

1276

O15085
APSLDVHMDSPDINI

AHNAK

4951

Q09666
VHMDSPDINIEGPDV

AHNAK

4956

Q09666
DMSFELPCHCKPEEV

FAM187A

46

A6NFU0
AEDMFDHPTPCELIK

CDC42EP3

201

Q9UKI2
LPVHPDVLDESCMFE

CASP8AP2

1396

Q9UKL3
EDLLAHLEPTCAAME

DUSP28

76

Q4G0W2
IMDLLEDPACVPDIN

ATP10B

796

O94823
MLECPETVNTLLHEF

ABHD8

401

Q96I13
NPHLIIMNVSDCIPD

OSMR

791

Q99650
HILANECDLMESIEP

RAB38

176

P57729
QLAEQACPHDVEMTP

LLGL1

691

Q15334
PIECSQRSAHELPMV

NFATC2

566

Q13469
DEVDKMCHLPEPELN

PRKCQ

351

Q04759
MSLEQRSPHCKPDED

MAGEA9

1

P43362
IDQMRDHVPPVSLVC

LSG1

461

Q9H089
EQLIPMEHVQIPDCV

ATCAY

306

Q86WG3
EVEILVCGSPDLDMH

HECTD2

656

Q5U5R9
RAHACPAVEETPMNV

GPR50

351

Q13585
LMHAVDPEIPQAVCI

GDF3

316

Q9NR23
TMEEIEHTCPQPRLT

PCYT1B

26

Q9Y5K3
ALENDPDCRHVIPMN

PLS3

136

P13797
AEEKENHCPTMLRPL

KIF22

501

Q14807
MVHCADLSNPTKPLE

PDE4A

586

P27815
RRDPQVSPMHCLDEE

COL18A1

641

P39060
CPPQDHDMQGLAERI

PRKD2

861

Q9BZL6
HDIPMIAQVTDCLPE

LRP2BP

276

Q9P2M1
QLEDFPMDAHACPLK

GABRA5

176

P31644
AHMCVPPALDEALSD

FOXC2

346

Q99958
PVLQVLHCGDESMLD

DDX41

561

Q9UJV9
ISEKCHENAPEPDSM

LRRIQ1

711

Q96JM4
GLCDNMEPETFLDHE

MED18

41

Q9BUE0
TVPDATPECPHQEMD

ITGAD

136

Q13349
TPECPHQEMDIVFLI

ITGAD

141

Q13349
DVVLLCGDLNMHPED

SMPD2

171

O60906
VMPCEDDHHLPTVQF

RPA1

286

P27694
RHLEEVEPEMPCVPQ

IL4R

521

P24394
QELGPLEPEEMIEHC

DSCC1

231

Q9BVC3
QLLESILMECAAEHP

DOCK2

1151

Q92608
IEQDFPKPEMLDLHC

CPLANE1

2721

Q9H799
DTADHPCVITMNPAL

CASC2

71

Q6XLA1
EPLHSILLTMCEDQP

FRMPD2

131

Q68DX3
PKQPLEVHETVAECM

DIS3L

671

Q8TF46
CAPVLHVVPAVSDME

AXIN1

746

O15169
MGRLHCTEDPVPEAV

COMMD7

1

Q86VX2
CIDVMVHFDLPGQEE

ATAD3C

291

Q5T2N8
EDADLPCHLFPTMSA

BTN3A2

46

P78410
ADELMHRECLPPSTV

HOXC11

96

O43248
EGAMHIQECVPEDLE

CRYL1

86

Q9Y2S2
ILSSMDPTVDPCHDF

ECE1

111

P42892
CLDPLQFMSLHIPEE

RYR2

1621

Q92736
ATLECHPLTMTDPIE

KIF2C

241

Q99661
IPDFPMHLACPEEED

PPRC1

271

Q5VV67
PNIIDHFLCDVDPLM

OR11H7

171

Q8NGC8
NMEIPHFFCDPSEVL

OR7C2

171

O60412
HSVCMGLLEESIPEQ

PHF20L1

706

A8MW92
LAPEIIECSMNEDHP

PHKG1

191

Q16816
ETLEMLPTCDLADQH

MAP3K15

306

Q6ZN16
LPPCHDSEESMEVFK

MAP3K7CL

46

P57077
DSGIAEMEELPVPHN

PHYHIPL

41

Q96FC7
DTMLPVCDHPDTAFT

PRUNE2

1961

Q8WUY3
LDPCDLQPIFDDMLH

TNFRSF21

591

O75509
IPQDVTEDCGMAEHL

RIF1

1131

Q5UIP0
RVSMEDAHNCIPELD

PPM1G

36

O15355
PHEEPSNSLMAIECR

PPARG

126

P37231
DLDIPNPMEASETVH

SMG1

2831

Q96Q15
ELEVLCPEMLHVAPA

SLITRK3

606

O94933
EDECALMLLEHGTDP

POTEJ

181

P0CG39
QELMEQLEHCELAPP

SHKBP1

596

Q8TBC3
ETLEQDGTVMLPDCH

MYCBP2

441

O75592
PEEPHFVQEDMVCAG

PRSS8

211

Q16651
APQEHERILDMCCAP

NOP2

381

P46087
PNEDEMPNRCGIIHV

SRRT

631

Q9BXP5
AEPEEHSVRICMSPG

CNGB1

1216

Q14028
VLCDHMVDGQPLAED

RNF213

2501

Q63HN8
DRVMEVFLVPADPHC

USP4

486

Q13107
CLEHLNMEDNDIPGI

TLR3

356

O15455
DLPCIENVTDHDISM

RALGAPA1

461

Q6GYQ0
IENSCDPVLDLHMSL

MPDZ

886

O75970
AMDELHCDIDPLDNS

TRPM3

1431

Q9HCF6
FHSDTCLPLRPQEME

SUZ12

566

Q15022
CLPLRPQEMEVDSED

SUZ12

571

Q15022
HPLPKQESDQCVMEV

TFF2

71

Q03403
DDQPDLPELLHLEAM

STAM

321

Q92783
LVNHMIVSPDLPCDA

SGSM1

571

Q2NKQ1
SMESNEEEPVHLPCN

TRAV26-2

26

A0A0B4J265
QHESEEPFMPEERCL

C2orf88

21

Q9BSF0
PFIPSASEHMLKDCE

XPOT

721

O43592
EEHCKMPEAGEEQPQ

XAGE1A

66

Q9HD64
MDPDELPLDEHCERL

KDR

806

P35968
MEADVPAPACAAEEH

TXLNB

626

Q8N3L3
AAEEHVAAMVPACEP

TXLNB

636

Q8N3L3
FAPPEFLLEVQCMHE

TRUB2

216

O95900
AEVLEAVMPHLDQTP

UBE4A

681

Q14139
PTPTCEAHLVQDMEG

ZNF831

1056

Q5JPB2
SIIMDPDEVPLDEQC

FLT1

796

P17948
LTPPVLEEMGHCDSV

CCT8

336

P50990
DECALMLLEHGTDPN

POTEH

256

Q6S545
LMILGIPEDCNHEEF

PNMA8C

26

A0A1B0GUJ8
AHTVEAPSPETICEM

TOX4

526

O94842
VDESPPDFEIHITMC

TERF2IP

266

Q9NYB0
PDFEIHITMCDDDPP

TERF2IP

271

Q9NYB0
HITMCDDDPPTPEED

TERF2IP

276

Q9NYB0
HEMETEKVSEPECPA

KMT2D

1071

O14686
TPIDEGHLPMINQDE

PRKCH

656

P24723